You are here

Article Text

Article menu
Download PDFPDF
Adult nursing
Cohort study
Newer drugs to treat prostate symptoms are associated with increased risk of falls
  1. Maw Pin Tan1,2,
  2. Azad Hassan Abdul Razack3
  1. 1Division of Geriatric Medicine, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;
  2. 2Ageing and Age-Associated Disorders Research Group, University of Malaya, Kuala Lumpur, Malaysia;
  3. 3Division of Urology, Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  1. Correspondence to: Dr Maw Pin Tan, Department of Medicine, Faculty of Medicine University of Malaya, Kuala Lumpur 50603, Malaysia; mptan{at}ummc.edu.my
View Full Text

http://dx.doi.org/10.1136/eb-2016-102315

Statistics from Altmetric.com

    Commentary on: Welk B, McArthur E, Fraser LA, et al. The risk of fall and fracture with the initiation of a prostate-selective α antagonist: a population based cohort study. BMJ 2015;351:h5398.OpenUrlAbstract/FREE Full Text

    Implications for practice and research

    • Prostate-selective α-antagonists are associated with a small increased risk of falls and fall-related fractures.

    • Healthcare practitioners should consider counselling patients on the increased risk for falls prior to starting prostate-selective α-antagonists.

    • Future studies should evaluate strategies to reduce the risk of falls in men prescribed α-antagonists.

    Context

    Lower urinary tract symptoms (LUTS) due to prostate enlargement are almost ubiquitous among older men. α-Antagonists relax the smooth muscle of the prostate to help improve voiding. However, as α-antagonists are associated with the side effects of hypotension and dizziness due to their action on peripheral …

    View Full Text

    Footnotes

    • Funding University of Malaya Grand Challenge Fund (grant number GC002B-14HTM).

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/